Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from InMed Pharmaceuticals ( (INM) ).
InMed Pharmaceuticals reported its first quarter fiscal 2026 financial results, highlighting progress in its lead program INM-901, which targets Alzheimer’s disease. The company is advancing IND-enabling activities and has strengthened its board with two new directors. Financially, InMed closed the quarter with $9.3 million in cash, despite a slight decrease in revenue from its BayMedica commercial business. The company plans to continue advancing its pharmaceutical pipeline, with expectations of increased research and development expenses.
The most recent analyst rating on (INM) stock is a Sell with a $2.50 price target. To see the full list of analyst forecasts on InMed Pharmaceuticals stock, see the INM Stock Forecast page.
Spark’s Take on INM Stock
According to Spark, TipRanks’ AI Analyst, INM is a Underperform.
InMed Pharmaceuticals’ overall stock score is primarily hindered by its financial performance and valuation concerns. The persistent operational losses and negative cash flows are significant risks. Technical analysis indicates a mildly bearish to neutral trend. The recent $5M private placement is a positive development, but it does not outweigh the broader financial challenges.
To see Spark’s full report on INM stock, click here.
More about InMed Pharmaceuticals
InMed Pharmaceuticals Inc. is a pharmaceutical drug development company that focuses on creating a pipeline of proprietary small-molecule drug candidates aimed at addressing diseases with high unmet medical needs.
Average Trading Volume: 77,483
Technical Sentiment Signal: Sell
Current Market Cap: $4.85M
For an in-depth examination of INM stock, go to TipRanks’ Overview page.